BioTime to Present at Oppenheimer 27th Annual Healthcare Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 20, 2017--
BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company
developing and commercializing products addressing degenerative
diseases, today announced that Russell Skibsted, Chief Financial
Officer, will be presenting at the Oppenheimer 27th Annual
Healthcare Conference at the Westin Grand Central in New York City on
March 21, at 3:55 p.m. Eastern Time.
A webcast of Mr. Skibsted’s presentation at this conference will be
available at https://www.veracast.com/webcasts/opco/healthcare2017/06110342543.cfm.
Replays of the presentation will be available on BioTime’s website at www.biotimeinc.com.
BioTime is a clinical-stage biotechnology company focused on developing
and commercializing products addressing degenerative diseases. Our
clinical programs are based on two platform technologies: pluripotent
stem cells and cell/drug delivery platform technologies. The foundation
of our core therapeutic technology platform is pluripotent cells that
are capable of becoming any of the cell types in the human body. The
foundation of our cell delivery platform is its HyStem® cell and drug
delivery matrix technology. The Company’s current clinical programs are
targeting three primary sectors, aesthetics, ophthalmology and cell/drug
delivery. We also have significant equity holdings in two publicly
traded companies, Asterias Biotherapeutics, Inc. (“Asterias”) and
OncoCyte Corporation (“OncoCyte”), which we founded and which, until
recently, were our majority-owned consolidated subsidiaries.
BioTime common stock is traded on the NYSE MKT and TASE under the symbol
BTX. For more information, please visit www.biotimeinc.com
or connect with the company on Twitter,
Certain statements contained in this release are “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Statements pertaining to future financial and/or
operating results, future growth in research, technology, clinical
development, and potential opportunities for BioTime, Inc. and its
subsidiaries and affiliates, along with other statements about the
future expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements that
are not historical fact (including, but not limited to statements that
contain words such as “will,” “believes,” “plans,” “anticipates,”
“expects,” “estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties,
including, without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, and maintenance of intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with
the many uncertainties that affect the business of BioTime, Inc. and its
subsidiaries and affiliates, particularly those mentioned in the
cautionary statements found in more detail in the “Risk Factors” section
of its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q
filed with the SEC (copies of which may be obtained at www.sec.gov).
Subsequent events and developments may cause these forward-looking
statements to change. BioTime specifically disclaims any obligation or
intention to update or revise these forward-looking statements as a
result of changed events or circumstances that occur after the date of
this release, except as required by applicable law.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170320005286/en/
Source: BioTime, Inc.
EVC Group, Inc.
Brian Moore, 310-770-0389
Gotham Communications, LLC
Bill Douglass, 646-504-0890